Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 5/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19028056 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL30562670 | 0.81 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL27784703 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL845583 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL23776735 | 0.78 | SMN1; SMN2 (0.34) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KDM4E | |
| SCHEMBL27344761 | 0.78 | SMN1; SMN2 (0.42) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL31459178 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL3450931 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1PIK3C3KMT2A | |
| SCHEMBL29118334 | 0.76 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1MAPK1KDM4ENAPRT | |
| SCHEMBL17675169 | 0.76 | ALDH1A1 (0.40) | SMN1; SMN2ALDH1A1MAPK1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2012-04-26 | — | — | US | disclosed |
| WO-2011024004-A1 | HETEROCYCLIC UREA DERIVATIVES USEFUL FOR TREATMENT OF BACTERIAL INFECTION | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | WO | disclosed |
| EP-2262801-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009106885-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101100-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 | UROD, UMPS, SLC14A1 | SMN1; SMN2 2886/4885ALDH1A1 1208/4885MAPK1 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.